Objective: Coinfection with hepatitis C virus (HCV) is a major cause of morbidity and mortality among individuals with HIV. Our objective was to assess the prognostic performance of noninvasive measures of liver fibrosis in predicting all-cause mortality in women with HIV/HCV coinfection.
Introduction
Coinfection with hepatitis C virus (HCV) leads to significant morbidity and mortality in HIV-infected individuals [1] . Assessment of liver disease severity, including the degree of hepatic fibrosis, is important in counseling patients with HCV and determining the need for treatment. Efforts have focused on the identification of noninvasive methods of assessing fibrosis that avoid the limitations of liver biopsy, which is costly, invasive and does not always stage fibrosis accurately [2, 3] . Noninvasive methods include serum markers and transient elastography. Transient elastography has been shown to predict mortality in HIV/HCV-coinfected patients but cannot be studied retrospectively [4, 5] . We have previously found that both aspartate aminotransferase (AST) to platelet ratio (APRI) and FIB-4 are independently associated with all-cause mortality in HIV/HCVcoinfected women in Women's Interagency HIV Study (WIHS) [6] . Although both tests are readily available, they are less sensitive and not specific as they lack biological plausibility as they measure markers of inflammation [alanine aminotransferase (ALT), AST] and platelets rather than so-called 'direct markers' of fibrosis, components of liver matrix and mediators of matrix remodeling. These latter components are incorporated in the enhanced liver fibrosis test, which uses hyaluronic acid, procollagen III aminoterminal peptide (PIIINP) and tissue inhibitor of matrix metalloproteinase (TIMP-1) [7, 8] . The aim of this study was to assess the performance of enhanced liver fibrosis (ELF) relative to other noninvasive markers in predicting all-cause mortality in women with HIV and HCV coinfection. We chose ELF as it has been validated in HCV monoinfection and other chronic liver diseases; it utilizes direct measures of extra cellular matrix components as noted above; and it has not yet been studied in HIV-infected individuals [7, 9] . Accurate serum markers of fibrosis in HIV and HCV coinfection would allow for more frequent measurements without requiring invasive and costly procedures. We chose all-cause mortality as prior work noted that death certificates have significant limitations and liver disease may have been the underlying or contributing cause of septic death, renal death or multisystem organ failure [6] .
Patients and methods

Human study participants
We studied participants of the Women's Interagency HIV Study (WIHS), the largest NIH-funded, prospective, multicenter cohort of women at risk for, or currently diagnosed with HIV [10] . This study was approved by the WIHS Executive Committee, and the Institutional Review Boards at the six participating WIHS study sites, including the University of California San Francisco Institutional Review Board. Enrolment of women in this study took place during 1994-1995 and again in [2001] [2002] . WIHS participants are seen twice yearly and undergo detailed histories, physical exams, structured interviews, laboratory testing and storage of serum samples. Study eligibility included women with HIV/ HCV coinfection at WIHS study entry as defined by detectable serum HCV RNA, positive HCV antibody, and positive HIV by western blot and at least one visit with available serum measures for AST, ALT and platelets. Biomarkers of fibrosis from all eligible women who died and from eligible women who were alive at last follow-up visit and exhibited either severe or no/minimal fibrosis by APRI and FIB-4 were compared. Availability of specimen for ELF measurement was also required for inclusion. HCV infection was documented by testing for antibody to HCV by second or third-generation (EIA: Ortho-Diagnostic Systems, Rochester, New York, USA) and testing for the presence of HCV RNA by HCV branched DNA (Quantiplex 2.0 branched chain DNAenhanced label amplification assay; Chiron, Emeryville, California, USA) and by RT-PCR (COBAS Amplicor HCV Detection Kit; Roche Diagnostic Systems, Pleasanton, California, USA). HIV RNA was measured using the isothermal nucleic acid sequence-based amplification method (NASBA/Nuclisens; BioMerieaux, San Diego, California, USA) with a detection limit of 80 copies/ml. Hepatitis B virus status was assessed via testing for the surface antigen (HBsAg) within the first year of entry into WIHS. The definition of HAART was based on the U.S. Department of Health and Human Services treatment guidelines (www.aidsinfo.gov) as previously described [6] .
Serum markers of fibrosis ELF (Siemens Healthcare Diagnostics, Tarrytown, New York, USA) utilizes direct serum measures of extracellular matrix components: hyaluronic acid, PIIINP and TIMP-1 were assayed on an automated IMMUNO 1 immunoanalyzer (Siemens Medical Solutions Diagnostics, Tarrytown, New York, USA). The assays are magnetic particle separation immunoassays and were identical to those used for the 2004 European Liver Fibrosis study [8] . The TIMP-1 and PIIINP assays each use two monoclonal antibodies (MAbs) that bind to independent binding sites on their respective antigens. The hyaluronic acid assay uses hyaluronic acid binding protein, which is isolated from bovine nasal septum, in the place of MAbs. The ELF markers were analyzed individually, and the results continually refereed to a set of quality standards to ensure accurate analysis. Tests were performed according to the manufacturer's instructions at iQur Limited, London, UK. We also used two indirect markers of liver fibrosis: APRI [11] and FIB-4 [12] with upper limit of normal for AST and ALT designated as 40 U/l. These measures can be calculated using readily available patient and laboratory data [AST, ALT, platelet count (10 9 /l) and age] as described [11, 12] . We defined women who had progressed to severe fibrosis by APRI more than 1.5 and FIB-4 above 3.25 as previously described [11, 12] ; those women with minimal or no liver fibrosis at all WIHS visits were defined as having APRI less than 0.5 and FIB-4 below1.5. Moderate fibrosis was defined as APRI above 0.5 but below 1.5 and FIB-4 above 1.5 but below 3.25 as previously described [11, 12] . ELF testing was performed on stored serum samples collected every 2 years during WIHS.
Statistical analysis
The performance of each marker was assessed by receiver operator characteristic (ROC) curves showing sensitivity and specificity for predicting death. We evaluated all fibrosis markers as predictors of all-cause mortality to compare their performance using the area under the curve (AUC). AUCs for each fibrosis marker were compared as predictors of mortality within 1 year, 1-3 years, 3-5 years, or 5-7 years before our last observation for each woman. We also constructed linear logistic regression models using all three fibrosis markers (ELF, FIB-4 and APRI) to determine whether a linear combination of markers performed better than any one marker. We tested for statistically significant differences between the curves using the methods implemented in PROC LOGISTIC of SAS 9.2 (SAS Institute, Cary, North Carolina, USA) [13] . Because differences in predictive power might arise from a serum marker's sensitivity to processes unrelated to liver disease but related to mortality, multivariate logistic regression models were developed, adjusting for CD4 þ , HIV viral load, antiretroviral (HAART) use and age. We believed that these were the four available variables that could plausibly influence both fibrosis markers and risk of death. Results from logistic regression employed fibrosis markers that were dichotomized as severe or nonsevere fibrosis using standard cutoff values of 10.43 for ELF, 3.25 for FIB-4 and 1.5 for APRI as described [11, 12, 14] .
Results
Cohort characteristics
We included 381 HIV/HCV-coinfected women with a mean follow-up of 8.3 AE 3.3 years. Table 1 shows the characteristics of all HIV/HCV-coinfected women at last available visit. One hundred and thirty-four of these women died during the study. Mean duration of follow-up was shorter for women who died (7.9 AE 3.3 years) than for women who were alive at last visit (8.6 AE 3.3 years). Overall, the majority (63.0%) of women were African American. Of these, 44.4% of women had hypertension, 6.6% reported injecting drugs and 1.3% were HBsAg positive. These HIV/HCV-coinfected women had modest elevations of ASTand ALT. ASTwas higher among women who died. Those who died had poorer HIV control, as shown by higher last visit (P < 0.001) and peak (P ¼ 0.013) HIV viral loads, lower CD4 þ cell count at last visit (P < 0.001) and nadir (P < 0.001), and less use of antiretroviral therapy (ART) (P ¼ 0.0025). They also had lower BMI (P < 0.0001), worse renal disease (as measured by both estimated glomerular filtration rate (eGFR, P ¼ 0.014) and the proportion of women with eGFR <60 ml/min: P < 0.0001). The primary cause of death reported on the death certificate was AIDS in 37 women; infection in 24 (16 lung, one neurologic, sevenunspecified); liver related in18; cancer in13; alcoholand drugabusein11; other [cardiac (six), renal (six), multiorgan (two), gastrointestinal (two) and one each pulmonary hypertension, neurologic, accident and psychiatric]; and HIV positive indeterminate cause in 11. No data were available about secondary causes of death. Only 6.2% of women had ever received HCV therapy at the time of this analysis. fibrosis and 78 had severe fibrosis. Nearly all (96.3%) women had three or more ELF measurements, and 60% had six or more ELF measurements. Figure 1 shows the ROC curves at year of death or last visit. ELF was best at predicting all-cause mortality with AUC of 0.85, compared with AUC for FIB-4 of 0.75 (P ¼ 0.004 ELF vs. FIB-4) and AUC for APRI of 0.69 (P < 0.001 ELF vs. APRI). The AUC for the model, which utilized all three markers, was 0.84, no better than ELF alone. At 2 years prior to death, ELF (AUC 0.71) continued to predict all-cause mortality better than FIB-4 (AUC 0.65; P ¼ 0.06) or APRI (AUC 0.61; P ¼ 0.005). However, its accuracy waned at 4 years (ELF AUC 0.67) and 6 years (ELF AUC 0.61) and it was not substantially better than FIB-4 or APRI at these time points. These data are shown in Supplemental Table 1 , http://links.lww.com/QAD/ A846.
Fibrosis assessment
The performance of the different predictors in univariate analyses and in multivariate analyses, adjusting for ART, CD4 þ , HIV viral load and age are shown in Table 2 . ELF was the only marker whose prediction of death remained statistically significant at all time periods. These results remained consistent whether CD4 þ cell count was used as a continuous variable (shown) or tricotomized with cutpoints of either less than 100, above 100-350 and more than 350, or below 200, above 200-500 and above 500 (data not shown). For predicting death within 1 year, ELF was the only marker whose effect increased with the addition of the other factors, from an odds ratio of 12.2 to 15.0. At 2 and 4 years prior to death, ELF performed best, but all markers' effects declined when adjusted for the other factors (Table 2 and supplemental Table 1 , http:// links.lww.com/QAD/A846). At 6 years prior to death, ELF again was the only measure whose magnitude of effect increased on adjustment for other factors ( Table 2 ). The percentage of women with severe fibrosis was greatest at year of death. HCV treatment did not have P < 0.05 when added to any of the multivariate models in Table 2 , and ELF continued to have larger odds ratios than APRI or FIB-4 in those models.
Discussion
This study showed that in a large cohort of women with HIV and HCV coinfection, ELF was better in predicting Multivariate analysis adjusting for log 10 CD4 þ cell count (current and nadir CD4 þ ), and log 10 HIV viral load, HAART use, and age as a continuous variable.
all-cause mortality than APRI and FIB-4. Using all three measures did not improve on the predictive value of ELF alone. To determine whether this superior performance was a consequence of ELF's sensitivity to nonliver-related causes of comorbidity, we compared the predictors' performance with and without adjusting for CD4 þ cell count, HIV viral load, HAART use and age in logistic regression models. In these multivariate models, ELF continued to have higher odds ratios than APRI and FIB-4 up to 6 years prior to death, but it was not superior after 3 years prior to death in univariate ROC curve analyses. We have previously shown that two indirect markers of hepatic fibrosis, APRI and FIB-4 scores, were independently predictive of mortality in 450 WIHS HIV/HCV-coinfected women on HAART [6] . Others have shown that APRI and FIB-4 are predictive of liver fibrosis in HIV/HCV-coinfected individuals but most accurate for diagnosis of cirrhosis [15] . These tests are currently widely available in clinical practice as they are derived from algorithms that combine commonly measured serum analytes. Nevertheless, they were found to be inferior to ELF in this current study. We performed an analysis to address the possibility of selection bias with a model weighted by the sampling fractions in women with different degrees of fibrosis defined by APRI and FIB-4. This sensitivity analysis provided similar results, which is evidence against selection bias accounting for the apparent superiority of ELF over APRI and FIB-4.
Tissue injury leads to ongoing extracellular matrix remodeling with fibrogenesis and the production of proteins such as TIMP and fibrolysis with degradation by metalloproteinases [16] . If fibrogenesis exceeds fibrolysis, then fibrosis is the net result [17] . Mild fibrosis leads to mild functional compromise but with ongoing progression, cirrhosis develops with elevation of portal pressure, shunting of blood from the liver and impaired synthetic and metabolic activity. The assessment of the extent of fibrosis is much more difficult in the absence of the clinical findings of advanced disease. In the United States, liver biopsy has been considered the gold standard for determining the degree of hepatic fibrosis. But we have previously estimated that only 37% of samples from patients with true stage 3 fibrosis were accurately classified by liver biopsy [3, 18] . In addition, liver biopsy is invasive and costly, which limits the frequency of measurements, further compromising its utility as a monitoring tool. Fewer measurements also make it difficult to average out measurement error. Even liver biopsy performs poorly in the differentiation of minor and moderate degrees of fibrosis [18] . WIHS is an observational cohort and few women had liver biopsies. We assessed the three serum fibrosis markers against all-cause mortality rather than liver biopsy because of these limitations. As we studied stored serum samples, we could not assess transient elastography as another noninvasive assessment of liver fibrosis. The analytes measured by ELF are stable over protracted storage at -70 (Siemens IFU and data on file). An advantage of serum-based tests over transient elastography is the ability to study stored serum samples, to replicate frequently and lack of failure to test that is reported with transient elastography. Transient elastography is increasingly being used as an alternative to liver biopsy in many centers and its association with mortality in HIV/HCV-coinfected individuals has been demonstrated [5, 19] . Because we studied individuals retrospectively, we did not have such data on transient elastography. Transient elastography is subject to a failure rate of 5-15% in the best hands and is influenced by inflammation, obesity and inter-operator variability [20, 21] . None of these are true for ELF, making it more amenable to routine use in both hospital and communitybased settings. In a number of published studies, equivalent performance has been reported for ELF and LSM (when successful), and in 'intention to diagnose' analyses, ELF outperforms LSM [21] [22] [23] .
As noted in previous work, death certificates have certain limitations and liver disease may have been the underlying cause of septic death, renal death or multisystem organ failure but we were not able to verify this [6] . As noted in Table 2 , a higher proportion of women who died had severe fibrosis, suggesting that liver fibrosis may have played a role even in women reported to have died from HIV or nonliver causes. For this reason, we assessed allcause mortality and showed that ELF was the best predictor of death in these HIV/HCV-coinfected women.
Serum markers of fibrosis have been studied for some years and different tests measure a variety of proteins including acute phase reactants; proteins of fibrinolysis and fibrogenesis; as well as breakdown products of inflammatory response or collagen deposition [9, 11, 24, 25] . The ideal measure of fibrosis in serum should be an accurate measure of the amount of liver fibrosis, and should to be able to distinguish between stages of fibrosis and predict the onset of complications of fibrosis. It should be reproducible, validated in large cohorts, and able to be monitored over time. ELF has been shown to be of prognostic value for both all-cause, and liver-related morbidity and mortality in a range of liver diseases including hepatitis C but HIV patients were not included [7] . Our results are similar to those reported in HCV-monoinfected individuals [12, 5] . ELF has also been shown to be useful in assessing fibrosis progression and clinical liver decompensation in different types of liver disease, including hepatitis C, primary biliary cirrhosis and nonalcoholic fatty liver disease [14, 26, 27] . However many of these studies did not include women and this is the first study showing that ELF predicts death in HIV/HCV-coinfected individuals. ELF could be useful in stratifying patients to identify those HCV patients at greatest and most immediate risk of liver decompensation and in need of new all oral HCV therapies.
